Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ARRY 3.50 +0.13 (3.86%)
price chart
Stocks Buzz: Array Biopharma Inc (ARRY), Smith & Wesson Holding Corp ...
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Related articles »  
Climbing NASDAQ Stocks: Endocyte, Inc.(NASDAQ:ECYT), Array Biopharma Inc ...
New York, NY - 09/24/2014 - HotStockGains provides investors and traders with valuable trading strategies via text message and email.
Related articles »  
Big Movers : Array BioPharma (NASDAQ:ARRY), Mondelez International ...
On October 10, Array Biopharma's Inc (NASDAQ:ARRY) for LMNA-related dilated cardiomyopathy is highly speculative and has a high risk of failure, said Summer Street analyst Bart Classen.
Related articles »  
Traders Recap - Array Biopharma Inc (ARRY), BioScrip Inc (NASDAQ:BIOS ...
Array Biopharma Inc (NASDAQ:ARRY) Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.
Morning Summary: UTi Worldwide, Array BioPharma, HMS Holdings, Oncolytics ...
UTi Worldwide Inc. (NASDAQ:UTIW) has implemented solutions from Axway for enterprise-level integration across its regional IT departments.
Active Movers � Array Biopharma Inc (NASDAQ:ARRY), ASTELLAS PHARMA ...
Array Biopharma Inc (NASDAQ:ARRY) opened the session at $3.61, trading in a range of $3.33-$3.62, and closed at $3.48. The stock showed a negative performance of -2.52% in the last trading session.
Array Biopharma Hits New 1-Year Low at $3.34 (ARRY)  Watch List News (press release)
Related articles »  
Stock Summary: Akorn Inc,Alkermes plc,Spectrum Pharma,Sequenom,Array ...
Array BioPharma Inc. (NASDAQ:ARRY) licensed to Novartis (NVS) in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2.
Related articles »  
Big Movers: eBay Inc. (NASDAQ:EBAY), Array BioPharma, Inc. (NASDAQ:ARRY ...
Earlier this year, eBay Inc. (NASDAQ:EBAY) waged a costly and bitter campaign dubbed �Better Together� to counter investor Carl Icahn's calls to spin off its PayPal payments unit.
Related articles »  
Traders Ditching Biotech Names: VIVUS, Inc. (VVUS), XOMA Corp (XOMA ...
VIVUS, Inc. (NASDAQ:VVUS), XOMA Corp (NASDAQ:XOMA), Array Biopharma Inc (NASDAQ:ARRY), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) all were down as riskier stocks such as technology, ...
Array Biopharma Sees Large Increase in Short Interest (ARRY)
Analysts expect that Array Biopharma will post $-0.79 EPS for the current fiscal year. Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted ...
Stocks Buzz � Interface, (NASDAQ:TILE), TrueCar, (NASDAQ:TRUE), Apollo ...  Techsonian (press release)
Related articles »